Cryo Cell International Inc (CCEL) — SEC Filings

Cryo Cell International Inc (CCEL) — 20 SEC filings. Latest: 8-K (Nov 12, 2025). Includes 9 8-K, 6 10-Q, 2 DEF 14A.

View Cryo Cell International Inc on SEC EDGAR

Overview

Cryo Cell International Inc (CCEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 12, 2025: On November 12, 2025, CRYO CELL INTERNATIONAL, INC. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporated in Delaware and its principal executive offices are located in Oldsmar, Florida.

Sentiment Summary

Across 20 filings, the sentiment breakdown is: 2 bearish, 18 neutral. The dominant filing sentiment for Cryo Cell International Inc is neutral.

Filing Type Overview

Cryo Cell International Inc (CCEL) has filed 9 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 10-Q/A with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (20)

Cryo Cell International Inc SEC Filing History
DateFormDescriptionRisk
Nov 12, 20258-KCryo-Cell International Files 8-Klow
Oct 23, 20258-KCryo-Cell International Enters Material Definitive Agreementmedium
Oct 15, 202510-QCryo-Cell's Q3 Net Income Plunges 28.7% Amid Rising Interest Costshigh
Sep 26, 2025DEF 14ACryo-Cell Sets Oct. 21 Shareholder Meeting for Director Elections, Auditor Ratificationlow
Sep 10, 20258-KCryo-Cell International Files 8-K Reportlow
Jul 15, 202510-QCryo-Cell's Losses Widen Amidst Revenue Dip; Secures New Credit Linehigh
May 22, 20258-KCryo-Cell International Terminates Material Agreementmedium
May 8, 20258-KCryo-Cell International Files 8-Klow
Apr 14, 202510-QCryo Cell International Inc. Files Q1 2025 10-Qmedium
Feb 28, 202510-KCryo Cell International Files 2024 10-Kmedium
Oct 31, 20248-KCryo-Cell International Reports on Shareholder Votelow
Oct 30, 20248-KCryo-Cell International Files 8-Klow
Oct 17, 202410-Q/ACryo-Cell International Files Q3 2024 Amendmentlow
Oct 15, 202410-QCryo Cell International Inc. Files Q3 2024 10-Qmedium
Oct 7, 2024DEF 14ACryo-Cell International Files Proxy Statement for Annual Meetinglow
Sep 17, 20248-KCryo-Cell International Files 8-Klow
Jul 15, 202410-QCryo Cell International Inc. Files Q2 2024 10-Qmedium
Apr 15, 202410-QCryo Cell International Files 10-Q for Feb 2024medium
Mar 26, 20248-KCryo-Cell International Files 8-Klow
Feb 28, 202410-KCryo Cell International Inc. Files 2023 Annual Report on Form 10-Kmedium

Risk Profile

Risk Assessment: Of CCEL's 20 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Cryo Cell International Inc Financial Summary (10-Q, Oct 15, 2025)
MetricValue
Revenue$7.83M
Net Income$1.39M
Cash Position$265,207

Key Executives

  • David I. Portnoy
  • Mark L. Portnoy
  • Harold D. Berger
  • Daniel Mizrahi
  • Jill Taymans
  • Oleg Mikulinsky

Industry Context

The stem cell banking industry, while offering long-term health benefits, is capital-intensive and subject to evolving regulatory landscapes. Companies in this sector often face challenges related to customer acquisition costs, technological advancements, and the long-term storage and management of biological materials. Competition can arise from both established players and new entrants.

Top Tags

8-K (4) · 10-Q (4) · financials (4) · 8-k (3) · filing (3) · sec-filing (3) · other-events (2) · Biotechnology (2) · Stem Cell Banking (2) · Financial Performance (2)

Key Numbers

Cryo Cell International Inc Key Metrics
MetricValueContext
SEC File Number001-40767Identifies the company's filing history with the SEC.
IRS Employer Identification No.22-3023093Company's tax identification number.
Total Revenue$7.83MDecreased by 2.9% for the three months ended August 31, 2025, compared to $8.07M in the prior year.
Net Income$1.39MDecreased by 38.7% for the nine months ended August 31, 2025, compared to $2.26M in the prior year.
Cash and Cash Equivalents$265,207Decreased by 52.8% from $560,960 at November 30, 2024, to August 31, 2025.
Interest Expense$1.58MIncreased by 41.5% for the nine months ended August 31, 2025, compared to $1.12M in the prior year.
Losses on Marketable Securities$604,619A significant reversal from $1.06M in gains for the nine months ended August 31, 2024.
Dividends Paid$3.23MA new cash outflow for the nine months ended August 31, 2025, with no dividends paid in the prior year.
Total Stockholders' Deficit$14.83MIncreased from $13.22M at November 30, 2024, to August 31, 2025.
Net Cash from Operating Activities$4.20MIncreased from $3.85M for the nine months ended August 31, 2024, to August 31, 2025.
Annual Meeting DateOctober 21, 2025Date for Cryo-Cell International, Inc.'s Annual Meeting of Stockholders
Record DateSeptember 15, 2025Date for determining stockholders entitled to vote at the Annual Meeting
Shares Outstanding8,062,159Number of common shares outstanding on the record date
Director Nominees4Number of individuals nominated for election to the Board of Directors
Board Meetings8Number of Board of Directors meetings held during fiscal year ended November 30, 2024

Related Companies

CRYO

Frequently Asked Questions

What are the latest SEC filings for Cryo Cell International Inc (CCEL)?

Cryo Cell International Inc has 20 recent SEC filings from Feb 2024 to Nov 2025, including 9 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CCEL filings?

Across 20 filings, the sentiment breakdown is: 2 bearish, 18 neutral. The dominant sentiment is neutral.

Where can I find Cryo Cell International Inc SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cryo Cell International Inc (CCEL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cryo Cell International Inc?

Key financial highlights from Cryo Cell International Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CCEL?

The investment thesis for CCEL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cryo Cell International Inc?

Key executives identified across Cryo Cell International Inc's filings include David I. Portnoy, Mark L. Portnoy, Harold D. Berger, Daniel Mizrahi, Jill Taymans and 1 others.

What are the main risk factors for Cryo Cell International Inc stock?

Of CCEL's 20 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 10 low-risk.

What are recent predictions and forward guidance from Cryo Cell International Inc?

Forward guidance and predictions for Cryo Cell International Inc are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.